Buchumschlag

Editorial: Mesenchymal Stem Cell Therapy for Perianal Fistulising Crohn's Disease—Effective or Hype?

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Jeffrey D McCurdy, Serre‐yu Wong
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2024
Schlagworte:	Alimentary Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Editorial: Seton Use in Perianal Fistulising Crohn's Disease. Authors' Reply
von: Jeffrey D McCurdy, et al.
Veröffentlicht: (2025)

Systematic Review of Published Guidelines: Recommendations for Exams Under Anaesthesia, Seton Insertion and Timing of Seton Removal for Perianal and Rectovaginal Fistulising Crohn's Disease
von: Edgard Medawar, et al.
Veröffentlicht: (2026)

Editorial: Examining Perianal Fistulising Crohn's Disease Through the Lens of Wound Repair
von: Tim Eglinton
Veröffentlicht: (2025)

Letter: Re‐Examining Seton Efficacy in Perianal Crohn's Disease—Critical Considerations for Outcome Measurement and Clinical Interpretation. Authors' Reply
von: Jeffrey D. McCurdy, et al.
Veröffentlicht: (2025)

Evaluation of the Effectiveness and Safety of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease: An International Real‐Life Retrospective Multicentre Cohort Study
von: Péter Bacsur, et al.
Veröffentlicht: (2024)

Letter: Real‐Life Evaluation of Effectiveness of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease Emphasises the Importance of Appropriate Patient Selection and Centre Expertise
von: Weilun Gao, et al.
Veröffentlicht: (2024)

Editorial: Fistula Calprotectin as a Biomarker of Local Inflammation and Treatment Response in Perianal Fistulising Crohn's Disease. Authors' Reply
von: Runqi Wang, et al.
Veröffentlicht: (2026)

Letter: Real‐Life Evaluation of Effectiveness of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease Emphasises Importance of Appropriate Patient Selection and Centre Expertise—Authors' Reply
von: Péter Bacsur, et al.
Veröffentlicht: (2024)

Editorial: Upadacitinib in Perianal Crohn's Disease
von: Manjeet Kumar Goyal, et al.
Veröffentlicht: (2026)

Correction to ‘Stromal Vascular Fraction With Platelet‐Rich Plasma Injection During Surgery is Feasible and Safe in Treatment‐Refractory Perianal Fistulising Crohn's Disease: A Pilot Study’
Veröffentlicht: (2024)

One‐Year Effectiveness of Upadacitinib in Perianal Crohn's Disease: A Real‐World GETAID Study
von: Nicolas Richard, et al.
Veröffentlicht: (2026)

Fistula Calprotectin as a Biomarker of Local Inflammation and Treatment Response in Perianal Fistulizing Crohn's Disease
von: Runqi Wang, et al.
Veröffentlicht: (2026)

Editorial: Real‐World Evidence of Upadacitinib—An Effective Induction Therapy for Crohn's Disease?
von: C. Ramos‐Belinchon, et al.
Veröffentlicht: (2025)

Editorial: Development and Validation of a Multimodal Machine Learning Model for Diagnosing and Assessing Risk of Crohn's Disease in Patients With Perianal Fistula
von: Alyssa M. Parian, et al.
Veröffentlicht: (2025)

Letter: Re‐Examining Seton Efficacy in Perianal Crohn's Disease—Considerations for Outcome Measurement and Clinical Interpretation
von: Dingsheng Liu, et al.
Veröffentlicht: (2025)

Editorial: Real‐World Evidence of Upadacitinib—An Effective Induction Therapy for Crohn's Disease? Authors' Reply
von: Nicolas Richard, et al.
Veröffentlicht: (2025)

Editorial: Development and Validation of a Multimodal Machine Learning Model for Diagnosing and Assessing Risk of Crohn's Disease in Patients With Perianal Fistulae: Authors' Reply
von: Lichao Qiao, et al.
Veröffentlicht: (2025)

Letter: Putting Crohn's Risk Prediction to Work in Perianal Fistula—Calibration, Thresholds, and Transport
von: Emmanuel Pio Pastore
Veröffentlicht: (2025)

Editorial: Upadacitinib—A Promising Induction Agent for Paediatric Crohn's Disease?
von: Vincenzo Stranges, et al.
Veröffentlicht: (2025)

Research Communication: Combination Therapy of Upadacitinib With Infliximab, Risankizumab, Ustekinumab or Vedolizumab for Refractory Crohn's Disease: A Descriptive Case Series
von: Rahul S. Dalal, et al.
Veröffentlicht: (2025)

Editorial: Endoscopic Activity is an Essential Tool for Patients' Management, Even in Mild Crohn's Disease
von: Marco Mendolaro, et al.
Veröffentlicht: (2025)

Editorial: Beyond Resection—Rethinking Postoperative Management in Colonic Crohn's Disease. Authors' Reply
von: José Luis Rueda García, et al.
Veröffentlicht: (2026)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease
von: Tamar Schildkraut, et al.
Veröffentlicht: (2024)

Editorial: “Striding” Towards Transmural Healing: Redefining Deep Remission as a Treatment Target in Crohn's Disease
von: Rohita Reji, et al.
Veröffentlicht: (2026)

Letter: Crohn's Disease or Comorbidity? Reassessing Opioid Prescribing Patterns
von: Kuan‐Ju Lin, et al.
Veröffentlicht: (2025)

Inflammatory Potential of the Diet and Risk of Crohn's Disease and Ulcerative Colitis
von: Antoine Meyer, et al.
Veröffentlicht: (2025)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease—Authors' Reply
von: Virginia Solitano, et al.
Veröffentlicht: (2024)

Letter: Inflammatory Potential of the Diet and Risk of Crohn's Disease and Ulcerative Colitis
von: Zhidong Zhou, et al.
Veröffentlicht: (2025)

Upadacitinib for Induction of Remission in Paediatric Crohn's Disease: An International Multicentre Retrospective Study
von: Shlomi Cohen, et al.
Veröffentlicht: (2025)

Letter: The Simple Endoscopic Score for Predicting Crohn's Disease Progression—Not as Simple as It Sounds
von: Ziheng Calvin Xu, et al.
Veröffentlicht: (2025)

Editorial: The prevalence and outcomes of perianal Crohn's disease across treatment eras
von: Daniel Tassone, et al.
Veröffentlicht: (2024)

Editorial: Infliximab induction therapy in pediatric Crohn's disease—A cost‐effective strategy?
von: Neil Chanchlani, et al.
Veröffentlicht: (2024)

Letter: ‘Early Ileal Resection in Crohn's Disease Is Not Associated With Severe Long‐Term Outcomes: The ERIC Study’
von: Matthias Kelm, et al.
Veröffentlicht: (2025)

Network Meta‐Analysis: Comparative Efficacy of Biologics and Small Molecules in the Induction and Maintenance of Remission in Crohn's Disease
von: Mohammad Shehab, et al.
Veröffentlicht: (2025)

Crohn's Disease With Latent Tuberculosis Infection or Intestinal Tuberculosis: Rapid Discrimination by Targeted Next‐Generation Sequencing
von: Lingna Ye, et al.
Veröffentlicht: (2025)

Performance of bowel preparation quality scales in patients with Crohn's disease
von: Virginia Solitano, et al.
Veröffentlicht: (2024)

Leucine‐Rich Alpha‐2 Glycoprotein Is Associated With Transmural Inflammation Assessed by Intestinal Ultrasound in Patients With Crohn's Disease
von: Moeko Komatsu, et al.
Veröffentlicht: (2024)

Letter: Early Inflammatory Benefit Is Not Yet Equivalent to Durable Surgical Advantage After Colectomy in Colonic Crohn's Disease
von: Jiacheng Li
Veröffentlicht: (2026)

Letter: Crohn's Disease With Latent Tuberculosis Infection or Intestinal Tuberculosis: Rapid Discrimination by Targeted Next‐Generation Sequencing
von: Maryam Irshad, et al.
Veröffentlicht: (2025)

Letter: Early Ileal Resection in Crohn's Disease Is Not Associated With Severe Long‐Term Outcomes: The ERIC Study: Authors' Reply
von: Nathan Grellier, et al.
Veröffentlicht: (2025)